Hybridoma cell strain capable of secreting anti-canine PD-L1 monoclonal antibody and application of hybridoma cell strain
By developing hybridoma cell lines and corresponding kits that secrete anti-dog PD-L1 monoclonal antibodies, the problem of lack of special detection tools in the prior art was solved, and the preparation of high-purity antibodies and detection of PD-L1 in canine tumors was realized. Improved accuracy.
Patent Information
- Application Number
- CN202411184631.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-08
AI Technical Summary
The PD-L1 detection products for canine tumors in the prior art lack specialized detection tools, resulting in low clinical response rates and limited prognosis of predictive biomarkers for immunotherapy.
A hybridoma cell line secreting anti-dog PD-L1 monoclonal antibody was developed. The antibodies secreted by the cell line were used to prepare a kit for detecting dog tumor PD-L1, including colloidal gold immunotherapy kit and chemiluminescence reagent. Cassettes, radioimmune kits, enzyme-linked immunity kits or fluorescent immunity kits are used to detect PD-L1 in canine tumor tissues.
The preparation and application of high-purity anti-dog PD-L1 monoclonal antibody was realized, and the immunohistochemistry detection method was optimized, providing a reliable tool for the detection of PD-L1 in canine tumor tissues, improving the accuracy and feasibility of the detection. sex.
Smart Images

Figure CN118909964A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biotechnology, and particularly relates to a hybridoma cell line secreting an anti-canine PD-L1 monoclonal antibody and an application thereof. Background Art
[0002] As the life span of pet dogs increases, cancer is becoming a common cause of death in dogs. Similar to human cancer, current treatments for canine cancer include surgical resection, chemotherapy, and radiotherapy. In addition, some molecular targeted therapies, including tyrosine kinase inhibitors, can be used to treat some types of canine cancer, such as mast cell tumors. New treatment paradigms are being developed to find new directions for the treatment of canine cancer. Immunotherapy is a promising strategy, and some targeted antibodies have been developed and tested in vitro and in vivo.
[0003] Programmed Cell Death 1Ligand 1 (PD-L1) is a key immunosuppressive molecule that balances immune responses and promotes autoimmune tolerance by regulating the immune system's response to body cells and inhibiting T cell activity. Its ligand PD-L1 is often overexpressed in tumor cells and binds to PD-1 in vivo, thereby transmitting immunosuppressive signals and reducing T cell proliferation and activation. This phenomenon suggests that the PD-1 / PD-L1 pathway is one of the main mechanisms for tumors to achieve immune escape. In human medical studies, PD-L1 expression is upregulated on tumor cells or tumor microenvironments such as tumor-infiltrating lymphocytes, and it reduces T cell activity by binding to PD-1 on tumor antigen-specific T cells. By blocking the PD-1 / PD-L1 pathway using anti-PD-1 or anti-PD-L1 antibodies, the various effector functions of T cells can be restored, thereby effectively alleviating the progression of cancer.
[0004] Canine PD-1 immunotherapy has made some progress in the veterinary field, but it still has the disadvantage of low clinical response rate. The same is true in human medicine. Although immunotherapy has great prospects, only a small number of patients achieve a lasting response to monotherapy, so predictive biomarkers are used for the prognosis of immunotherapy. However, there are no products specifically used to detect PD-L1 in canine tumor tissue in the domestic market. Summary of the invention
[0005] In order to overcome the above-mentioned shortcomings and deficiencies of the prior art, the primary object of the present invention is to provide a hybridoma cell line that secretes anti-canine PD-L1 monoclonal antibodies.
[0006] Another object of the present invention is to provide an anti-canine PD-L1 monoclonal antibody secreted by the above hybridoma cell line.
[0007] Another object of the present invention is to provide a use of the above anti-canine PD-L1 monoclonal antibody in preparing a kit.
[0008] The purpose of the present invention is achieved through the following solutions:
[0009] A hybridoma cell line that secretes anti-canine PD-L1 monoclonal antibodies, the hybridoma cell line is classified as mouse hybridoma cell, and was deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration on May 15, 2024, with the deposit number CGMCC No.45860.
[0010] The present invention also provides an anti-canine PD-L1 monoclonal antibody, which is obtained by secreting the above hybridoma cell line.
[0011] Furthermore, the anti-canine PD-L1 monoclonal antibody of the present invention is an IgM subtype monoclonal antibody.
[0012] The present invention also provides the use of the hybridoma cell line secreting the anti-canine PD-L1 monoclonal antibody or the anti-canine PD-L1 monoclonal antibody in preparing a kit for detecting canine tumor PD-L1.
[0013] Furthermore, the kit is a kit based on immunoassay.
[0014] Furthermore, the kit is a colloidal gold immunoassay kit, a chemiluminescence kit, a radioimmunoassay kit, an enzyme-linked immunosorbent assay kit or a fluorescent immunoassay kit.
[0015] The present invention also provides a kit for detecting canine tumor PD-L1, which comprises the hybridoma cell line secreting the anti-canine PD-L1 monoclonal antibody or the anti-canine PD-L1 monoclonal antibody.
[0016] The present invention also provides the use of the hybridoma cell line secreting the anti-canine PD-L1 monoclonal antibody or the anti-canine PD-L1 monoclonal antibody in preparing a canine tumor diagnostic reagent.
[0017] Furthermore, the tumor includes at least one of breast cancer, skin cancer, nasal adenocarcinoma, transitional cell carcinoma, soft tissue sarcoma, osteosarcoma, melanoma, diffuse large B-cell lymphoma, ovarian cancer, kidney cancer, liver cancer, lung cancer, colorectal cancer, and prostate cancer.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] The hybridoma cell line of the present invention (named G6D-4) can stably secrete anti-canine PD-L1 monoclonal antibodies. The present invention uses G6D-4 to prepare ascites antibodies and purifies them by Protein A affinity chromatography to obtain high-purity anti-canine PD-L1 monoclonal antibodies with a concentration of 0.44 mg / mL. The present invention uses G6D-4 monoclonal antibody as the primary antibody, collects clinical canine tumor samples, optimizes immunohistochemical conditions, and establishes a canine PD-L1 immunohistochemical detection method. This lays the foundation for the subsequent construction of a commercial canine tumor tissue PD-L1 immunohistochemical detection kit. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 Restriction digestion and identification of pCold II-cPD-L1 recombinant plasmid; 1: DL12000 DNAMarker; 2: pCold II-cPD-L1 recombinant plasmid was digested by BamH I and Sal I at two sites; 3: pCold II-cPD-L1 recombinant plasmid.
[0021] Figure 2 PCR identification of pCold II-cPD-L1 recombinant plasmid; 1: 5000 DNA Marker; 2-5: monoclonal bacterial solution; 6: negative control.
[0022] Figure 3 This is the prokaryotic expression of canine PD-L1 recombinant protein; 1: protein marker; 2, 3, 5: precipitates obtained after induced expression; 4, 6: supernatants obtained after induced expression.
[0023] Figure 4 Purification and identification of canine PD-L1 recombinant protein; A: SDS-PAGE electrophoresis results; B: Western blotting results; 1-2: before purification of expression product; 3: protein marker; 4-7: after purification of expression product.
[0024] Figure 5 The standard curve for protein concentration determination by BCA method.
[0025] Figure 6 Purification of anti-canine PD-L1 monoclonal antibody; 1: protein marker; 2: before antibody purification; 3: flow-through; 4-6: eluent 1-3; 7: after antibody purification.
[0026] Figure 7 The standard curve for protein concentration determination by BCA method.
[0027] Figure 8 ELISA method for identifying monoclonal antibody subtypes; 1: G6D-4 monoclonal antibody; 2: negative control; 3: positive control.
[0028] Fig. 9 These are the results of immunohistochemical staining of clinical canine tumor tissues.
[0029] Fig.10 Screening of the best immunohistochemical conditions; A: different primary antibody working concentrations. A1: 1:1 dilution; A2: 1:10 dilution; A3: 1:20 dilution; A4: 1:50 dilution; A5: 1:100 dilution; A6: 1:200 dilution; B: different antigen retrieval conditions. B1: pH 6.0 sodium citrate antigen retrieval solution; B2: pH 8.0 EDTA antigen retrieval solution; C: different secondary antibody working concentrations. C1: 1:100 dilution; C2: 1:500 dilution; C3: 1:1000 dilution; C4: 1:2000 dilution; D: different DAB color development time. D1: color development 2min; D2: color development 5min; D3: color development 10min; D4: color development 15min. DETAILED DESCRIPTION
[0030] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0031] Example 1: Cloning and expression of canine PD-L1 gene
[0032] 1. Test methods
[0033] 1 Construction of canine PD-L1 prokaryotic expression vector
[0034] 1.1 Synthesis of target gene
[0035] According to the canine PD-L1 protein 3D map (E2RKZ5) published on the protein database (UniProt), the protein amino acid sequence of the extracellular segment was found to be 19-134aa. Then, the protein coding gene of the extracellular segment of the corresponding canine PD-L1 gene (GenBank: MT635411.1) on the National Center for Biotechnology Information (NCBI) (sequence as shown in SEQ ID NO.1) was used as the target gene, connected between the BamH I restriction site and the Sal I restriction site of the pCold II vector, and sent to General Bio (Anhui) Co., Ltd. for synthesis.
[0036] SEQ ID NO.1: TTTACAATAACTGTAAGTAAAGATCTATATGTCGTGGA GTACGGCGGTAATGTTACCATGGAATGTAAATTCCCGGTCGAGAAACAGTTGAACCTGTTTGCGTTAATCGTGTACTGGGAAATGGAGGACAAAAAGATCATCCAATTTGTGAACGGCAAAGAAGACTTGAAGGTGCAGCACAGCAGCTATTCCC AACGTGCGCAGTTGCTGAAGGACCAGCTCTTCCTGGGTAAGGCTGCCCTGCAGATTACCGATGTTCGTCTGCAAGATGCGGGGTTTACTGCTGCCTGATTGGCTATGGTGGCGCAGATTACAAGCGCATTACGCTGAAAGTTCATGCACCGTAT.
[0037] 1.2 Small-scale extraction of plasmid
[0038] In this experiment, the plasmid was extracted using the plasmid extraction kit from Tiangen Biochemical Technology (Beijing) Co., Ltd.
[0039] 1.3 Enzyme digestion identification of plasmid
[0040] (1) Enzyme digestion: The partial plasmid obtained in step 1.2 was subjected to double enzyme digestion identification. The enzyme digestion system was 20 μL and the reaction was performed at 37° C. for 30 min. The reaction system is shown in Table 1:
[0041] Table 1 Enzyme digestion reaction system
[0042] Components Volume (μL) Plasmids 2 CutSmart Buffer 2 BamH 1 Sal I 1 <![CDATA[ddH2O]]> 14
[0043] After cutting, run 1% agarose gel electrophoresis for identification.
[0044] (2) Agarose gel electrophoresis detection:
[0045] ① Add 1×TAE to the working tank of the electrophoresis apparatus and put in the prepared agarose gel;
[0046] ② Add DNA Marker and samples to the gel wells in sequence, and adjust the voltage to 150V for electrophoresis;
[0047] ③ When the electrophoresis indicator runs to the lower middle part of the gel block, pause the electrophoresis, take out the gel block, and observe the enzyme cutting results.
[0048] 1.4 Conversion
[0049] The recombinant plasmid was named pCold II-cPD-L1 according to its properties and transformed into BL21 competent cells.
[0050] 1.5 Screening of positive clones
[0051] (1) After overnight culture, four monoclonal colonies were picked from the plate and placed in 2 mL of ampicillin-resistant LB liquid culture medium to set up a negative control group. The culture was shaken overnight at 37°C in a shaker;
[0052] (2) Using the bacterial solution and the negative control as templates, a 25 μL reaction system was prepared as shown in Table 2 below, and PCR amplification was performed as shown in Table 3 below;
[0053] Table 2 Bacterial liquid PCR identification system
[0054] Components Volume (μL) Template (bacterial solution) 1 Taq enzyme mix 12.5 pCold-F 1 pCold-R 1 <![CDATA[ddH2O]]> 9.5
[0055] pCold-F (SEQ ID NO.2): 5'-ACGCCATATCGCCGAAAGG-3';
[0056] pCold-R (SEQ ID NO. 3): 5'-GGCAGGGATCTTAGATTCTG-3'.
[0057] Table 3 PCR reaction conditions
[0058]
[0059] (3) Agarose gel electrophoresis detection
[0060] 2 Prokaryotic expression of canine PD-L1 recombinant protein
[0061] 2.1 Inducible expression and identification of canine PD-L1 recombinant protein
[0062] (1) The positive bacterial solution screened in 1.5 was inoculated into ampicillin-resistant LB liquid medium at a ratio of 1:100 and cultured in a shaking incubator at 37°C until the bacterial solution OD 600 Value to 0.6;
[0063] (2) Add IPTG to a final concentration of 1 mM to the bacterial solution and express overnight at 15°C and 180 rpm;
[0064] (3) Take 1 mL of bacterial solution, centrifuge at 12000 rpm for 2 min, and discard the supernatant;
[0065] (4) Resuspend the pellet in 400 μL PBS and sonicate in an ice bath for 5 min until the liquid becomes clear.
[0066] (5) The bacterial suspension after ultrasonic disruption was centrifuged in a low-temperature centrifuge at 4°C, 10,000 rpm for 10 min, and the precipitate and supernatant were collected for SDS-PAGE identification. The steps are as follows:
[0067] ① Sample treatment: Take 20 μL 6× loading buffer and 80 μL sample and mix thoroughly, and heat at 100℃ for 10 min;
[0068] ② Centrifugation: Centrifuge the heated sample at 12000rpm for 8min to remove impurities and make the electrophoresis bands clearer;
[0069] ③ Loading: Place the prepared 15% SDS-PAGE gel in the electrophoresis tank, add an appropriate amount of 1× electrophoresis buffer, and add 20μL of sample and 5μL of Protein Marker to the sample wells respectively;
[0070] ④ Gel running: first set the voltage to 80V, and after the bromophenol blue indicator runs to the separation gel, increase the voltage to 160V. When the bromophenol blue indicator is found to be about 1cm away from the bottom, stop the electrophoresis;
[0071] ⑤ Staining: Remove the protein gel, stain it in Coomassie Brilliant Blue for 1 hour, recover the staining solution, and rinse the film twice with tap water;
[0072] ⑥ Decolorization: Pour an appropriate amount of decolorization solution into the container, making sure the liquid level covers the protein gel, place it in a microwave oven and heat for 30 seconds, and decolorize it overnight.
[0073] 2.2 Purification of canine PD-L1 recombinant protein
[0074] This experiment used the Ni Focurose 6FF (IMAC) affinity chromatography column of Wuhan Huiyan Biotechnology Co., Ltd. for protein purification. The specific steps are as follows:
[0075] (1) The bacterial solution obtained in the same step as in 2.1 was centrifuged at 10,000 rpm for 10 min at 4°C to collect the bacterial precipitate. The precipitate was resuspended in lysis buffer, and the suspension was ultrasonically disrupted. The suspension was centrifuged again under the same conditions. The precipitate was dissolved by shaking with 8 M urea overnight, and the obtained solution was purified;
[0076] (2) Water washing: Wash the medium with 5-10 column volumes (CV) of purified water at 2 mL / min;
[0077] (3) Equilibration: Equilibrate the medium with 5-10 CV of equilibration solution at 2 mL / min;
[0078] (4) Sample loading: Filter the sample in (1) (0.45 μm) and load it at 1 mL / min;
[0079] (5) Washing: Wash with 5-10 CV of washing solution at 2 mL / min and collect the washing solution;
[0080] (6) Elution: Use 5-10 CV of eluent at 2 mL / min and collect the eluate;
[0081] (7) Water washing: wash the medium with 5-10 CV of purified water at 2 mL / min;
[0082] (8) Storage: Wash the medium with 5-10 CV of 20% ethanol at 2 mL / min and store in a refrigerator at 4°C.
[0083] 2.3 Identification of purified canine PD-L1 recombinant protein
[0084] The purified recombinant protein was identified using SDS-PAGE electrophoresis and Western blotting. The specific steps are as follows:
[0085] (1) Gel running: Divide the sample into two portions according to the steps in 2.1 and perform SDS-PAGE gel electrophoresis simultaneously. Take one portion for Coomassie brilliant blue staining and destaining, and perform the following operations on the other portion;
[0086] (2) Transfer: Use the wet transfer method (sandwich method) to place the filter paper, cut protein gel, PVDF membrane and the second filter paper in sequence. Note that the PVDF membrane needs to be activated in methanol for 15-60 seconds. Connect the wet electrotransfer instrument to the power electrode according to the instructions, then place the electrotransfer instrument in ice water, set the current to 200 mA, and transfer for 1 hour;
[0087] (3) Blocking: Take out the PVDF membrane and place it in a blocking solution prepared with 5% skim milk for 1 h;
[0088] (4) Washing: Wash the PVDF membrane with TBST three times, 10 min each time;
[0089] (5) Incubation with primary antibody: Immerse the PVDF membrane in anti-His tag-mouse primary antibody and incubate at 4°C overnight;
[0090] (6) Washing: same as (4);
[0091] (7) Incubation with secondary antibody: immerse the PVDF membrane in appropriately diluted goat anti-mouse secondary antibody and incubate at room temperature for 1.5 h;
[0092] (8) Washing: same as (4);
[0093] (9) Exposure: Take out the PVDF membrane, absorb the TBST on the surface, immerse it in the developer, and after both sides are soaked, perform the exposure operation in the instrument.
[0094] 2.4 Renaturation of canine PD-L1 recombinant protein
[0095] (1) Slowly add the eluate obtained in step 2.2 to the protein refolding solution, slowly adding dropwise and paying attention to whether there is precipitation;
[0096] (2) The obtained solution was placed in a 7000D dialysis bag, placed in a dialysate containing 6 M urea, and dialyzed at 4°C for 12 h;
[0097] (3) Repeat (2) and place the sample into dialysis fluid containing 4M, 2M, and 0M urea in turn. The liquid in the dialysis bag is the renatured canine PD-L1 recombinant protein.
[0098] 2.5 Determination of the concentration of canine PD-L1 recombinant protein
[0099] This experiment uses the BCA protein quantification kit of Kangwei Century Biotechnology Co., Ltd. to determine the concentration of canine PD-L1 recombinant protein. The specific steps are as follows:
[0100] (1) Add 25 μL of the diluted AG BSA standard and the protein sample to be tested into a 96-well plate and repeat 2-3 wells;
[0101] (2) Add 200 μL of BCA working solution to each well, mix thoroughly, incubate in a 37°C incubator for 30 min, and then remove. After the liquid cools to room temperature, the test is completed within 3-5 min;
[0102] (3) Read the OD value of the sample at 562 nm using an ELISA reader and keep a record;
[0103] (4) Draw a protein standard curve and calculate the protein concentration.
[0104] 2. Test results
[0105] 1 Construction of canine PD-L1 prokaryotic expression vector
[0106] 1.1 Plasmid enzyme digestion identification results
[0107] In order to identify whether the pCold II-cPD-L1 recombinant plasmid was successfully constructed, the synthetic recombinant plasmid was double-digested with restriction endonucleases BamH I and Sal I. The results are shown in Figure 1 As shown in the results, the recombinant plasmid produced bands of 4380 bp and 360 bp respectively after enzyme digestion, which was consistent with the expected results.
[0108] 1.2 Positive cloning results of strains
[0109] In order to identify whether the canine PD-L1 recombinant protein prokaryotic expression vector was successfully constructed, the bacterial solution of the single clone was used as a template, and PCR amplification was performed on the bacterial solution when the negative control was not turbid. The results are as follows: Figure 2 As shown in the results, it can be seen that the constructed canine PD-L1 recombinant protein prokaryotic expression vector can successfully amplify the canine PD-L1 gene.
[0110] 2 Prokaryotic expression of canine PD-L1 recombinant protein
[0111] 2.1 Prokaryotic expression results of canine PD-L1 recombinant protein
[0112] In order to obtain canine PD-L1 recombinant protein, the pCold II-cPD-L1 positive cloning vector was cultured, and the expression was induced at low temperature by adding IPTG of appropriate concentration and ultrasonic disruption. The precipitate and supernatant were collected to prepare protein samples for SDS-PAGE electrophoresis test to observe the prokaryotic expression results of canine PD-L1 recombinant protein and whether the canine PD-L1 recombinant protein was soluble protein or inclusion body protein. The results are as follows Figure 3 As shown in the results, the pCold II-cPD-L1 positive cloning vector expressed the target protein in the precipitate after induction expression, and the target protein was mainly inclusion body.
[0113] 2.2 Purification results of canine PD-L1 recombinant protein
[0114] In order to obtain a high purity canine PD-L1 recombinant protein for subsequent experiments, the obtained canine PD-L1 recombinant protein was purified by Ni Focurose 6FF (IMAC) affinity chromatography column, and the protein samples obtained during the purification process were identified by SDS-PAGE electrophoresis and Western blotting. The results are as follows Figure 4 As shown in the results, the eluate contains the target protein with clear bands, and the purity of the canine PD-L1 recombinant protein is ≥85% after calculation by the gel imaging system.
[0115] 2.3 Results of concentration determination of canine PD-L1 recombinant protein
[0116] According to the OD values corresponding to the BSA standard proteins at various concentrations, a standard curve y=0.2456x+0.0052 was drawn, R2=0.9972 ( Figure 5 The calculated concentration of canine PD-L1 recombinant protein was 0.48 mg / mL.
[0117] Example 2: Preparation and identification of anti-canine PD-L1 monoclonal antibodies
[0118] 1. Test methods
[0119] 1 Animal immunization
[0120] (1) Immunization subjects: Six 6- to 8-week-old BABL / c female mice were selected, one of which served as a negative control;
[0121] (2) First immunization: 250 μL Quick Antibody-Mouse 3W adjuvant and 250 μL canine PD-L1 recombinant protein were quickly mixed at a ratio of 1:1 to obtain an adjuvant-antigen mixture. Each experimental group of mice was intramuscularly injected with 80 μL of the adjuvant-antigen mixture. The immunized mice were ear-tagged and numbered: z71, z72, z73, z74, and z75;
[0122] (3) Second vaccination: 14 days after the first vaccination, give a booster shot in the same manner. Make sure to prepare the adjuvant and antigen freshly each time.
[0123] 2 Mouse serum titer determination
[0124] (1) Seven days after the second immunization, blood was collected from the mouse orbits, numbered, and kept at 4°C overnight to allow serum to precipitate;
[0125] (2) Antigen coating: Coat each well of the ELISA plate with 100 μL of diluted canine PD-L1 recombinant protein to ensure that the antigen content is 0.2 μg / well. Place the ELISA plate at 4°C overnight for coating;
[0126] (3) Washing: Use PBST washing solution, add 300 μL to each well, soak at room temperature for 1 min, then pat dry, and repeat three times;
[0127] (4) Blocking: Add 300 μL of skim milk to each well. Incubate the ELISA plate in a 37°C incubator for 2 h.
[0128] (5) Washing: same as step (3);
[0129] (6) Incubation with primary antibody: add 100 μL of the test serum to each well, and dilute it in a gradient: 1:1000, 1:2000, 1:4000, 1:8000, 1:16000, 1:32000, 1:64000, 1:128000, and incubate the ELISA plate in a 37°C incubator for 1 h;
[0130] (7) Washing: same as step (3);
[0131] (8) Incubation with secondary antibody: Add 100 μL of 1:10000 diluted goat anti-mouse secondary antibody to each well. Place the ELISA plate in a 37°C incubator and incubate for 2 h.
[0132] (9) Washing: same as step (3);
[0133] (10) Color development: Add 100 μL of single-component TMB color development solution VII to each well. Place the ELISA plate in the dark at room temperature for 10 min.
[0134] (11) Stop: Add 50 μL of stop solution to each well;
[0135] (12) Reading: Place the terminated ELISA plate into an ELISA reader, set the program to read the OD value at a wavelength of 450 nm, and save the data.
[0136] 3. Cell Fusion
[0137] 3.1 Thawing and culturing mouse myeloma SP2 / 0 cells
[0138] (1) Take out mouse myeloma SP2 / 0 cells from the liquid nitrogen tank and immediately place them in 36°C warm water and shake to thaw;
[0139] (2) Transfer the liquid in the cryotube to a 10 mL centrifuge tube, centrifuge at 1000 rpm for 5 min, discard the supernatant, add 1 mL of DMEM complete medium and mix by pipetting;
[0140] (3) Transfer cells to 25 cm 2 Add 5 mL of DMEM complete medium to the cell culture flask, shake well, and place flat in a cell culture incubator containing 5% CO2 and 37°C;
[0141] (4) During this period, the medium is changed according to the growth status of the cells and the cells are expanded to 75cm 2 Cell culture flask.
[0142] 3.2 Strengthening Immunity
[0143] Booster immunization was performed one week before cell fusion.
[0144] 3.3 Laying feeder cells
[0145] (1) One day before cell fusion, a 6-8 week old female BALB / c mouse was killed by cervical dislocation and then immersed in 75% alcohol for 5 min;
[0146] (2) Take out the sterilized mice, drain the alcohol, and place them on a clean bench;
[0147] (3) Cut open the mouse abdominal skin to expose the peritoneum, pick up the peritoneum with forceps, and inject 10 mL of DMEM incomplete culture medium into the peritoneum;
[0148] (4) Hold the mouse by its tail and gently shake it. After 1 min, use a syringe to aspirate the culture medium from the peritoneal cavity, place it in a centrifuge tube, centrifuge at 1000 rpm for 5 min, and discard the supernatant.
[0149] (5) Resuspend the cells with HAT complete medium, spread 100 μL per well of a 96-well plate, and culture in a cell culture incubator containing 5% CO 2 and 37° C.
[0150] 3.4 Obtaining mouse spleen cells
[0151] (1) Take immunized mice and completely remove the spleen of the mice;
[0152] (2) Place the mouse spleen in a 10 cm cell culture dish containing about 10 mL of DMEM incomplete culture medium and cut the spleen into small pieces with scissors;
[0153] (3) Place the cell screen on a 50 mL centrifuge tube, add the chopped mouse spleen, and grind it with the rubber tip of a syringe;
[0154] (4) Aspirate the culture medium from the culture dish to rinse the cell sieve, collect the solution in a centrifuge tube, centrifuge at 1000 rpm for 5 min, and discard the supernatant;
[0155] (5) Add 2 mL of red blood cell lysis buffer to the precipitate. After 1 min, terminate the reaction with 10 mL of DMEM incomplete medium. Centrifuge at 1000 rpm for 5 min and discard the supernatant.
[0156] 3.5 Preparation of hybridoma cells
[0157] (1) Obtain mouse myeloma SP2 / 0 cells: 75 cm 2 The cell culture flask was taken out, the culture medium was discarded, the cells were washed twice with PBS, and then they were patted down, resuspended with DMEM incomplete culture medium, and transferred to a centrifuge tube. The cells were centrifuged and resuspended twice under the same centrifugation conditions, and the supernatant was discarded to completely remove the serum.
[0158] (2) Resuspend SP2 / 0 and spleen cells in 20 mL of DMEM incomplete medium, count using a counting plate, mix in a 50 mL centrifuge tube at a ratio of SP2 / 0:spleen cells = 1:2, centrifuge at 1000 rpm for 5 min, and prepare 37°C warm water at this time;
[0159] (3) After centrifuging the cell suspension, discard the supernatant, then gently tap the centrifuge tube to loosen the cell pellet, and then immerse the bottom of the centrifuge tube in 37°C warm water;
[0160] (4) Cell fusion: Slowly and evenly add 1 mL of PEG preheated at 37°C into the cell pellet, mixing while adding, and the process lasts for 60 seconds;
[0161] (5) Incubate for 45 seconds, take out 1 mL of DMEM incomplete medium preheated at 37°C, and evenly drip it into the centrifuge tube within 60 seconds, then take another 1 mL and evenly drip it into the centrifuge tube within 30 seconds, and then slowly drip the remaining 45 mL into the centrifuge tube;
[0162] (6) Gently invert the tube to mix, centrifuge at 1500 rpm for 5 min, and discard the supernatant;
[0163] (7) Resuspend the cell pellet with HAT complete medium and culture in a cell culture incubator containing 5% CO2 and 37°C;
[0164] (8) After 7 days of culture, observe the cell status, perform a half-medium change with HT complete medium, and mark the holes with cell clusters under the microscope.
[0165] 4 Screening and subcloning of positive hybridoma cells
[0166] 4.1 Screening of positive cells
[0167] The indirect ELISA method was used to screen the positive cell wells: when the cells grew to 30% of the bottom area, 100 μL of culture medium was aspirated from each well and tested according to the ELISA method. The positive control was the positive serum collected and preserved from the corresponding immunized mice. The wells with the highest positive value were selected and retained for subcloning.
[0168] 4.2 Subcloning of positive cells
[0169] (1) Determine the number of positive cell subclones based on the number of selected positive cell wells, prepare feeder layer cells, and finally resuspend them in HT complete medium;
[0170] (2) Subcloning of positive cells using the limiting dilution method: Count the cells under a microscope and adjust the cell number to 1–5 × 10 2 / mL. Add 200μL / well to rows A and B of a 96-well cell culture plate. Use HT complete medium to dilute the remaining cells in multiples and add them to rows C and D. Repeat the multiple dilution operation until rows G and H are added. Culture in a cell culture incubator containing 5% CO2 and 37°C.
[0171] (3) Regularly observe the size of the cell clusters, and repeat 2.4.1 when the cells grow to 30% of the bottom area to screen out the positive cell wells. Repeat the subcloning three times to ensure that it is a single positive cell subclone and can stably secrete anti-canine PD-L1 antibodies.
[0172] 4.3 Proliferation and cryopreservation of positive cells
[0173] (1) Expansion of positive cells: The selected positive cell monoclonal hybridoma cells were plated in 96-well plates, 48-well plates, 24-well plates, 12-well plates, 6-well plates, and 25-cm plates. 2 The cell bottles were expanded sequentially, and indirect ELISA was performed regularly during the expansion process to ensure that the cell lines could stably secrete anti-canine PD-L1 antibodies;
[0174] (2) Cryopreservation of positive cells: Ensure that the expanded positive cells are in the logarithmic growth phase and in good condition.
[0175] ① Prepare cell freezing solution on the day of freezing;
[0176] ② 25cm 2 The old culture medium in the cell bottle was discarded, and the cells were washed twice with PBS, digested with 0.05% trypsin for 1 min, and then the digestion was terminated with the same volume of DMEM complete culture medium;
[0177] ③ Mix the adherent cells by pipetting and transfer them to a centrifuge tube, centrifuge at 1000 rpm for 5 min, and discard the supernatant;
[0178] ④ Resuspend with 2 mL of prepared cell freezing solution, aspirate 1 mL into each cell freezing tube, place the freezing tube in a programmed cooling box, and store in a -80℃ refrigerator for short-term freezing.
[0179] 5 Preparation and purification of ascites monoclonal antibodies
[0180] 5.1 Preparation of ascites monoclonal antibodies
[0181] (1) Mouse sensitization: Female BALB / c mice aged 6-8 weeks were selected and each mouse was intraperitoneally injected with 0.5 mL of Freund's incomplete adjuvant;
[0182] (2) Cell recovery culture: Recover frozen positive cell lines and culture them to the logarithmic growth phase;
[0183] (3) Cell inoculation: One week after the injection of adjuvant, 0.5 mL of hybridoma cells was injected into the peritoneal cavity of each mouse (the inoculation volume of hybridoma cells was controlled at 5 × 10 4 ~10 5 pcs / piece);
[0184] (4) Ascites extraction and storage: The abdomen of the mouse gradually swells in 7-15 days. At this time, ascites can be extracted, and 4-5 mL can be extracted each time. It can be extracted again after an interval of about 2 days. Generally, each mouse can be extracted 2-3 times. The extracted ascites should be centrifuged promptly at 3000 rpm for 25 minutes. After discarding the cell pellet, it can be frozen and stored in a -20℃ refrigerator.
[0185] 5.2 Column purification of ascites monoclonal antibodies
[0186] (1) Sample preparation: Take out the frozen mouse ascites, centrifuge at 12000 rpm and 4°C for 10 min, and collect the supernatant. Dilute the supernatant ten-fold with eluent 1, and filter through a 0.45 μm microporous membrane;
[0187] (2) Water washing: Wash the purifier and antibody column with purified water at a rate of 2 mL / min;
[0188] (3) Sample loading: The sample prepared in (1) was passed through the antibody column at a rate of 2 mL / min in a refrigerator at 4°C, and the flow-through was collected;
[0189] (4) Flushing: Connect tubes A and B of the purifier with eluent 1 and eluent 3 respectively, flush tube B first and then tube A at a rate of 10 mL / min, each for 2 min, until tubes A and B are filled with eluent 1 and eluent 3;
[0190] (5) First elution: Set the %B in the program to 0, the rate to 2.5 mL / min, and the time to 6 min. Then connect the loaded Protein A antibody column, and be careful to prevent air from entering the column. Collect 50 μL of waste liquid, which is recorded as elution liquid 1;
[0191] (6) Second elution: After the baseline is stable, replace the liquid in tube A with eluent 2, and the rate and time remain unchanged. Collect 50 μL of waste liquid, which is recorded as eluent 2;
[0192] (7) Third elution: After observing that the baseline is stable, adjust the %B in the program to 100, and keep the rate and time unchanged. Collect 50 μL of waste liquid and record it as elution liquid 3;
[0193] (8) Elution: After observing that the baseline is stable, replace the liquid in tube B with the eluent, keep the rate unchanged, and change the time to 14 minutes. When the elution peak is observed, collect the eluent. Add an appropriate amount of neutralizing buffer to the eluent to make the pH neutral;
[0194] (9) Regeneration: After observing that the baseline is stable, replace the liquid in tube B with the regeneration liquid at the same rate and change the time to 6 minutes;
[0195] (10) Water washing: After observing that the baseline is stable, replace the AB tube with purified water, adjust the %B in the program to 50, keep the rate unchanged, and change the time to 8 minutes;
[0196] (11) Storage: Remove the antibody column, connect a peristaltic pump, pass 20% ethanol through the antibody column at a rate of 2 mL / min, and then freeze the antibody column at 4°C;
[0197] (12) SDS-PAGE electrophoresis: detection of ascites dilution, flow-through, eluent 1, eluent 2, eluent 3 and eluate;
[0198] (13) Storage of purified monoclonal antibodies: The monoclonal antibody eluate that meets the standards is passed through a 0.45 μm disposable syringe filter and then frozen at 4°C.
[0199] 6. Determination of Monoclonal Antibody Concentration
[0200] The same procedure as in step 2.5 of Example 1 was used to draw a BSA standard curve and calculate the concentration of the anti-canine PD-L1 monoclonal antibody.
[0201] 7 Monoclonal Antibody Subtype Identification
[0202] This test uses the mouse monoclonal antibody Ig class / subclass identification ELISA kit produced by Beijing Biolong Immunotechnology Co., Ltd. to identify the subtype of monoclonal antibodies. The specific steps are as follows:
[0203] (1) Antigen coating: Coat each well of the ELISA plate with 100 μL of diluted canine PD-L1 recombinant protein to ensure that the antigen content is 0.2 μg / well. Place the ELISA plate at 4°C overnight for coating;
[0204] (2) Washing: Use PBST washing solution, add 300 μL to each well, soak at room temperature for 1 min, then pat dry, and repeat three times;
[0205] (3) Blocking: Add 300 μL of skim milk to each well. Incubate the ELISA plate in a 37°C incubator for 2 h.
[0206] (4) Washing: same as step (2);
[0207] (5) Incubation with primary antibody: Add 100 μL of diluted elution buffer to each well, add 6 wells for each monoclonal antibody, set up 6 wells of negative control and positive control, and incubate the ELISA plate in a 37°C incubator for 1 h;
[0208] (6) Washing: same as step (2);
[0209] (7) Incubation with secondary antibodies: Add 100 μL of each of the six enzyme-labeled secondary antibodies to the six wells of each monoclonal antibody, negative control, and positive control, and incubate the ELISA plate in a 37°C incubator for 1 h;
[0210] (8) Washing: same as step (2);
[0211] (9) Color development: Add 50 μL of color developer A and 50 μL of color developer B to each well, and place the ELISA plate at 37°C in the dark for 20 min.
[0212] (10) Interpretation: The results can be interpreted by naked eyes.
[0213] 2. Test results
[0214] 1 Mouse serum titer determination results
[0215] In order to determine the effect of canine PD-L1 recombinant protein as an antigen to immunize mice, the indirect ELISA method was used to detect the titer of the immunized mouse serum. The serum of unimmunized mice was used as a negative control, and the ELISA results are shown in Table 4. Calculate the positive and negative critical values, positive and negative critical values = negative control OD 450 Mean + SD. The results show that the titer of the sera of the immunized mice is higher than 1:16000, which meets the requirements of cell fusion. The z73 mice with the highest titer were selected for booster immunization to prepare for subsequent cell fusion.
[0216] Table 4 Determination of canine PD-L1 antibody titer in mouse serum after immunization
[0217] Serum dilution Z71 Z72 Z73 Z74 Z75 Negative control 1:500 1.6249 1.6446 1.6193 1.7671 1.6531 0.0736 1:1000 1.7233 2.1792 2.1037 2.2012 2.0344 0.0654 1:2000 1.2371 1.8619 2.0921 2.0751 1.8022 0.1247 1:4000 0.6545 0.8967 1.2744 1.2737 0.9443 0.0792 1:8000 0.3434 0.4503 0.6312 0.8686 0.5295 0.0456 1:16000 0.1657 0.2092 0.3331 0.3364 0.1686 0.0588 1:32000 0.0950 0.1284 0.2120 0.1997 0.0858 0.0346 1:64000 0.0687 0.0914 0.1153 0.1100 0.0691 0.0370
[0218] Note: Critical value of yin and yang = 0.094.
[0219] 2. Screening of hybridoma cells
[0220] In order to obtain hybridoma cell lines with strong specificity and the ability to stably secrete monoclonal antibodies, three hybridomas that can stably secrete anti-canine PD-L1 monoclonal antibodies were screened through three subcloning experiments and named G6D-2, G6D-4 and G6D-10. G6D-4 was selected for use in subsequent experiments.
[0221] G6D-4, i.e. cPD-L1 hybridoma cell G6D-4, classified as mouse hybridoma cell, was deposited in the General Microbiology Center of China Culture Collection Administration (CGMCC) on May 15, 2024. The deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 45860.
[0222] 3. Purification of monoclonal antibodies
[0223] In order to obtain a high-purity anti-canine PD-L1 monoclonal antibody for subsequent immunohistochemical detection, this experiment used the method of injecting sensitized mice with hybridoma cells in the logarithmic growth phase to obtain a large amount of ascites. After the ascites monoclonal antibody was centrifuged and roughly purified, it was purified by Protein A antibody column affinity chromatography. The purified product was identified by SDS-PAGE electrophoresis as shown in the figure below. Figure 6 As shown in the results, the eluate has obvious bands at 25kDa and 55kDa, and there is no obvious background band, indicating that the antibody was successfully purified and a monoclonal antibody with high purity was obtained.
[0224] 4. Determination of Monoclonal Antibody Concentration
[0225] According to the OD values corresponding to the BSA standard proteins at different concentrations, a standard curve y=1.041x+0.0108 was drawn, R 2 =0.9972( Figure 7 The calculated concentration of anti-canine PD-L1 monoclonal antibody was 0.44 mg / mL.
[0226] 5 Monoclonal Antibody Subtype Identification
[0227] In order to understand the subtype of the homemade monoclonal antibody, the subtype of the G6D-4 eluate was identified using the mouse monoclonal antibody Ig class / subclass identification ELISA kit from Beijing Biolong Immunotechnology Co., Ltd. The results are as follows Figure 8 As shown in the results, it can be seen that the subtype of G6D-4 monoclonal antibody is IgM.
[0228] Example 3: Optimization of immunohistochemical detection conditions for canine tumor PD-L1
[0229] 1. Test methods
[0230] 1. Preparation of paraffin tissue sections
[0231] (1) Fixation: The collected canine tumor tissues were placed in a fixative and fixed for more than 24 hours;
[0232] (2) Trimming: Use a scalpel to trim the tissue into small pieces;
[0233] (3) Dehydration, transparency and wax dipping: in an automatic dehydrator, the program is adjusted to 70% ethanol soaking for 4 h, 80% ethanol soaking for 1 h, 90% ethanol soaking for 1 h, 95% ethanol soaking for 1 h, 100% ethanol I soaking for 30 min, 100% ethanol II soaking for 20 min, ethanol:xylene = 1:1 soaking for 15 min, xylene I soaking for 5 min, xylene II soaking for 3 min, first-level wax soaking for 1 h, second-level wax soaking for 1 h, and third-level wax soaking for 1 h;
[0234] (4) Embedding: Place the tissue upright in an embedding box. It is easier to operate after the bottom of the metal embedding box is slightly solidified on a cold table.
[0235] (5) Sectioning: First, roughly cut (trim) to expose the tissue completely. Use 3-5 μm thickness for sectioning, spread the slices at 42°C for 10 seconds, air dry and dry after mounting, and save the white slices.
[0236] 2 Immunohistochemical staining
[0237] IHC was performed with positive serum, homemade primary antibody, negative serum and blank (PBS) control according to conventional methods, and positive tissues were selected for subsequent condition optimization experiments.
[0238] (1) Dewaxing: Dewaxing was performed according to the steps shown in Table 5;
[0239] Table 5 Tissue section dewaxing steps
[0240]
[0241]
[0242] (2) Washing: Use PBS, soak at room temperature for 5 min, then discard the liquid, and repeat 3 times;
[0243] (3) Antigen repair: Preheat the antigen repair solution in a microwave oven, immerse the washed slides in it, and heat at 20% microwave conditions for 3 minutes. Repeat 3 times. Take out the glass staining jar and wait for 1 hour to return to room temperature;
[0244] (4) Washing: same as step (2);
[0245] (5) H2O2 blocking: Take out the washed slides and lay them flat on a wet slide box. Use 3% H2O2 blocking solution to block for 20 minutes in the dark;
[0246] (6) Washing: same as step (2);
[0247] (7) Blocking: Use 5% BSA blocking solution and place in a 37°C incubator for 30 min;
[0248] (8) Primary antibody incubation: Incubate with diluted primary antibody at 4°C overnight;
[0249] (9) Washing: same as step (2);
[0250] (10) Secondary antibody incubation: Use diluted secondary antibody to block for 2 h at room temperature;
[0251] (11) Washing: same as step (2);
[0252] (12) Color development: Use the prepared DAB color development solution to develop the color for 5 min in the dark. After a positive result is obtained, use distilled water to terminate the reaction.
[0253] (13) Re-staining: After re-staining with hematoxylin for 2 minutes, rinse the slide with tap water. Then use hydrochloric acid alcohol to differentiate for 1 second, and rinse the slide with tap water. Finally, use blueing solution to blue for 1 minute, and rinse the slide with tap water;
[0254] (14) Dehydration and transparency: perform dehydration operation according to the steps shown in Table 6;
[0255] Table 6 Tissue section dehydration steps
[0256] Reagents Soaking time (min) Distilled water 1 50% ethanol 2 75% ethanol 2 85% ethanol 2 95% ethanol 2 Anhydrous ethanol 3 Xylene: anhydrous ethanol 1:1 5 Xylene I 5 Xylene II 5
[0257] (15) Sealing: Use neutral gum to seal the slides and evaporate the xylene in a fume hood;
[0258] (16) Observe and record the results under a microscope.
[0259] 3 Preliminary optimization of immunohistochemistry
[0260] 3.1 Determination of primary antibody working concentration
[0261] The homemade anti-canine PD-L1 monoclonal antibody G4D-4 was used as the primary antibody and diluted at a volume ratio of 1:1, 1:10, 1:20, 1:50, 1:100, and 1:200. Immunohistochemical staining was performed and the staining results were compared to determine the optimal working concentration of the primary antibody.
[0262] 3.2 Selection of antigen retrieval conditions
[0263] Select pH 6.0 sodium citrate antigen retrieval solution and pH 8.0 EDTA antigen retrieval solution, perform immunohistochemical staining, and compare the staining results to determine the optimal antigen retrieval conditions.
[0264] 3.3 Determination of working concentration of commercial secondary antibodies
[0265] The commercial goat anti-mouse secondary antibody was diluted at a volume ratio of 1:100, 1:500, 1:1000, and 1:2000, and immunohistochemical staining was performed. The staining results were compared to determine the optimal working concentration of the secondary antibody.
[0266] 3.4 Determination of DAB color development time
[0267] According to the instructions of the DAB colorimetric kit, 2 min, 5 min, 10 min and 15 min were selected as the colorimetric time, and immunohistochemical staining was performed. The staining results were compared to determine the optimal working time of the DAB colorimetric kit.
[0268] 3.5 Result determination
[0269] Observe the positive signal, i.e. the brown-yellow area, under a microscope. The absence of brown-yellow areas or cells is considered negative, while the presence of brown-yellow areas or cells is considered positive. Pay attention to the background staining intensity and the specific staining intensity.
[0270] 2. Test results
[0271] 1 Immunohistochemical staining results
[0272] The collected formalin-fixed canine tumor tissue was made into white slides, and positive serum, homemade primary antibody and negative serum were used as primary antibodies respectively. Another white slide was taken and PBS was used as blank control. The general immunohistochemical staining procedure was followed, and the results were as follows Fig. 9As shown. The results show that the use of positive serum or homemade monoclonal antibodies can make PD-L1 in canine tumor tissues color, and the color development sites are mainly concentrated in the cell membrane and cytoplasm. Negative serum and blank controls have no obvious positivity, indicating that the homemade anti-canine PD-L1 monoclonal antibody has application value in immunohistochemical detection. Using positive serum as the primary antibody, canine tumor tissue samples with positive signals were screened for subsequent immunohistochemical method optimization experiments.
[0273] 2. Determination of the optimal reaction conditions for immunohistochemistry
[0274] In order to determine the optimal reaction conditions for immunohistochemistry based on the homemade anti-canine PD-L1 monoclonal antibody, four conditions were detected, namely, the working concentration of the primary antibody, the antigen retrieval conditions, the working concentration of the commercial secondary antibody, and the DAB color development time. The results are shown in the figure. Fig.10 As shown in Table 7. The results show that the best results are obtained when the primary antibody concentration is 1:10, the sodium citrate antigen retrieval solution has a pH of 6.0, the secondary antibody concentration is between 1:100 and 1:500, and the DAB color development time is 5 to 10 min.
[0275] Table 7 Screening of optimal immunohistochemical conditions
[0276]
[0277] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. A hybridoma cell line secreting anti-canine PD-L1 monoclonal antibody, characterized in that: The hybridoma cell line is classified as mouse hybridoma cell, and was deposited in the General Microbiology Center of China National Microbiological Culture Collection Administration on May 15, 2024, with the deposit number CGMCC No.45860.
2. An anti-canine PD-L1 monoclonal antibody, characterized in that: The hybridoma cell line according to claim 1 is secreted.
3. The anti-canine PD-L1 monoclonal antibody according to claim 2, characterized in that: The anti-canine PD-L1 monoclonal antibody is an IgM subtype monoclonal antibody.
4. Use of the hybridoma cell line secreting the anti-canine PD-L1 monoclonal antibody according to claim 1 or the anti-canine PD-L1 monoclonal antibody according to claim 2 in the preparation of a kit for detecting canine tumor PD-L1.
5. The use according to claim 4, characterized in that: The kit is an immunoassay-based kit.
6. The use according to claim 5, characterized in that: The kit is a colloidal gold immunoassay kit, a chemiluminescence kit, a radioimmunoassay kit, an enzyme-linked immunosorbent assay kit or a fluorescence immunoassay kit.
7. A kit for detecting PD-L1 in canine tumors, characterized in that: The kit comprises the hybridoma cell line secreting the anti-canine PD-L1 monoclonal antibody according to claim 1 or the anti-canine PD-L1 monoclonal antibody according to claim 2.
8. Use of the hybridoma cell line secreting the anti-canine PD-L1 monoclonal antibody according to claim 1 or the anti-canine PD-L1 monoclonal antibody according to claim 2 in the preparation of a canine tumor diagnostic reagent.
9. The use according to claim 8, characterized in that: The tumors include breast cancer, skin cancer, nasal adenocarcinoma, transitional cell carcinoma, soft tissue sarcoma, osteosarcoma, melanoma, diffuse large B-cell lymphoma, ovarian cancer, kidney cancer, liver cancer, lung cancer, colorectal cancer, and prostate cancer.
